RxSight, Inc. (RXST)
| Market Cap | 187.59M -42.0% |
| Revenue (ttm) | 127.58M -13.2% |
| Net Income | -46.95M |
| EPS | -1.14 |
| Shares Out | 41.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,041,020 |
| Open | 4.700 |
| Previous Close | 4.670 |
| Day's Range | 4.495 - 4.830 |
| 52-Week Range | 4.400 - 13.220 |
| Beta | 1.14 |
| Analysts | Hold |
| Price Target | 7.57 (+67.66%) |
| Est. Earnings | Nov 4, 2026 |
About RXST
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be... [Read more]
Financial Performance
In 2025, RxSight's revenue was $134.48 million, a decrease of -3.89% compared to the previous year's $139.93 million. Losses were -$38.94 million, 41.8% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for RXST stock is "Hold." The 12-month stock price target is $7.57, which is an increase of 67.66% from the latest price.
News
K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world
K2 Vision has performed 5,000+ Light Adjustable Lens procedures and is recognized by RxSight as the highest-volume LAL practice in the world. Learn more.
RxSight price target lowered to $5.75 from $6.50 at Jefferies
Jefferies lowered the firm’s price target on RxSight (RXST) to $5.75 from $6.50 and keeps a Hold rating on the shares. The ophthalmology sector has been under pressure over the…
RxSight price target lowered to $5.50 from $6.50 at BofA
BofA lowered the firm’s price target on RxSight (RXST) to $5.50 from $6.50 and keeps an Underperform rating on the shares. Due diligence with doctors suggests structural barriers and competitive…
RxSight Transcript: Wells Fargo 21st Annual Healthcare Conference
Management is focused on revitalizing U.S. growth through deeper user engagement, education, and operational discipline, while leveraging the Alcon partnership and pipeline development for long-term market transformation. The business aims to return to growth by 2027, maintaining strong margins and capital efficiency.
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, S...
RxSight price target lowered to $7 from $8 at Stifel
Stifel lowered the firm’s price target on RxSight (RXST) to $7 from $8 and keeps a Hold rating on the shares. The firm updated its model following the Q2 10-Q…
RxSight price target raised to $6.30 from $5.50 at UBS
UBS raised the firm’s price target on RxSight (RXST) to $6.30 from $5.50 and keeps a Neutral rating on the shares.
RxSight says withdrawing guidance, will resume formal guidance in 2027
In connection with the leadership transition, RxSight (RXST) announced Wednesday that it withdrew 2026 guidance and will resume formal guidance in early 2027.
RxSight reports Q2 adjusted EPS (11c), consensus (19c)
Reports Q2 revenue $33.74M, consensus $32.55M. “It is a privilege to join RxSight (RXST) and to work alongside the talented team that pioneered an entirely new category in cataract surgery…
RxSight Earnings Call Transcript: Q2 2026
Q2 revenue reached $33.7M, with core product sales down 19% year-over-year amid competitive and market headwinds. The Alcon collaboration brought $6.5M in Q2 and is expected to contribute $30–$40M in 2026. Full-year guidance was withdrawn pending a strategic business assessment.
RxSight Earnings release: Q2 2026
RxSight released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
RxSight Quarterly report: Q2 2026
RxSight has published its Q2 2026 quarterly earnings report on August 5, 2026.
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
ALISO VIEJO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial o...
RxSight resumed with a Neutral at UBS
UBS resumed coverage of RxSight (RXST) with a Neutral rating with a price target of $5.50, down from $9. The eyecare sector is healthier than expected, with resilient U.S. consumer…
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
ALISO VIEJO, Calif., July 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on July 24, 2026, RxSight granted inducement stock options to purchase a total of 571,286 share...
RxSight Tarsus CEO Ron Kurtz to depart role, Aziz Mottiwala to succeed
RxSight (RXST) announced a planned leadership transition effective July 20, with Aziz Mottiwala appointed president and CEO, succeeding Ron Kurtz, who will continue to serve as chief medical officer. ...
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
ALISO VIEJO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced a planned leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and...
Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces it is investigating potential claims against the board of directors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST...
RxSight reports preliminary Q2 revenue $32M-$34M, consensus $32.07M
Yesterday, the company said that the preliminary revenue view includes $5M-$7M in revenue recognized from the RxSight (RXST) Alcon Strategic Collaboration, with the specific amount expected to be repo...
RxSight raises FY26 revenue view to $140M-$160M from $120M-$135M
Consensus $129.24M. The company said that the FY26 revenue view is inclusive of RxSight (RXST) sales and revenue recognized from the RxSight Alcon Strategic Collaboration, comprised of: Sales of $110M...
RxSight price target lowered to $6.50 from $7.50 at Jefferies
Jefferies lowered the firm’s price target on RxSight (RXST) to $6.50 from $7.50 and keeps a Hold rating on the shares. Q2 preliminary results missed due to competitive trialing and…
The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) concerning ...
RxSight price target lowered to $6.50 from $8 at BofA
BofA lowered the firm’s price target on RxSight (RXST) to $6.50 from $8 and keeps an Underperform rating on the shares. The firm notes the company pre-announced preliminary Q2 sales…
RxSight Transcript: Investor update
A new collaboration with Alcon will drive development of adjustable PC IOLs, expanding innovation and market reach. Q2 revenue declined due to competitive trialing, prompting revised 2026 guidance and increased commercial investment. The product pipeline and clinical differentiation remain key growth drivers.
RxSight Press release: Investor update
RxSight issued a press release on July 7, 2026, disclosing material business information to investors.